Journal article
A case of lenalidomide-induced hypersensitivity pneumonitis.
- Lerch E Oncology Institute of Southern Switzerland (IOSI), Ospedale San Giovanni, Bellinzona, Switzerland. erika.lerch@eoc.ch
- Györik S
- Feilchenfeldt J
- Mazzucchelli L
- Quadri F
- 2010-05-27
Published in:
- Onkologie. - 2010
Aged
Alveolitis, Extrinsic Allergic
Antineoplastic Agents
Diagnosis, Differential
Drug Hypersensitivity
Humans
Lenalidomide
Lung
Male
Multiple Myeloma
Thalidomide
Tomography, X-Ray Computed
English
BACKGROUND
Lenalidomide is a new immunomodulatory drug, FDA-approved for the treatment of the 5q-myelodysplastic syndrome and refractory or relapsed multiple myeloma (MM). Regarding the treatment of MM, there have been published cases of acute pulmonary toxicity for the proteasome inhibitor bortezomib and the immunomodulatory drug thalidomide; only 1 case of lenalidomide-induced pulmonary toxicity has been described in the literature.
CASE REPORT
In our manuscript, we describe the clinical course and diagnostic workup of a 66-year-old male patient with MM on lenalidomide with signs of acute pulmonary toxicity. The diagnostic workup resulted in the diagnosis of drug-induced interstitial hypersensitivity pneumonitis.
CONCLUSIONS
Given the frequently reported pulmonary infectious complications in patients treated with lenalidomide and a possibly underreported rate of interstitial pneumonitis, we advocate a more aggressive pulmonary workup for patients with pulmonary symptoms.
Lenalidomide is a new immunomodulatory drug, FDA-approved for the treatment of the 5q-myelodysplastic syndrome and refractory or relapsed multiple myeloma (MM). Regarding the treatment of MM, there have been published cases of acute pulmonary toxicity for the proteasome inhibitor bortezomib and the immunomodulatory drug thalidomide; only 1 case of lenalidomide-induced pulmonary toxicity has been described in the literature.
CASE REPORT
In our manuscript, we describe the clinical course and diagnostic workup of a 66-year-old male patient with MM on lenalidomide with signs of acute pulmonary toxicity. The diagnostic workup resulted in the diagnosis of drug-induced interstitial hypersensitivity pneumonitis.
CONCLUSIONS
Given the frequently reported pulmonary infectious complications in patients treated with lenalidomide and a possibly underreported rate of interstitial pneumonitis, we advocate a more aggressive pulmonary workup for patients with pulmonary symptoms.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1159/000305213
- PMID 20502059
- Persistent URL
- https://sonar.ch/global/documents/279167
Statistics
Document views: 43
File downloads: